Drug Trial Radar · NCT04115293
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
174
Actual
Start
Sep 17, 2019
Primary completion
Dec 30, 2021
Study completion Dec 30, 2021
Sponsor
- Lead sponsor
- Ra Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.
Conditions
- Myasthenia Gravis, Generalized
Interventions
zilucoplan (RA101495)Drug
Daily subcutaneous (SC) injection
PlaceboDrug
Daily subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline (CFB) to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total ScoreTime frame: From Baseline to End of Treatment (Week 12)
Locations
77 sites in 10 countries. Site status is shown where the registry gives one.
Site 41: Diagnostic and Medical Clinic
Mobile, Alabama
Site 116: Neuromuscular Clinic and Research Center
Phoenix, Arizona
Site 4: University of Southern California
Los Angeles, California
Site 31: University of California Irvine
Orange, California
Site 220: Investigator Site
Pasadena, California
Site 160: Forbes Norris MDA/ALS Research and Treatment Center
San Francisco, California
Site 24: Yale University
New Haven, Connecticut
Site 27: George Washington University
Washington D.C., District of Columbia
Site 182: Gelasio Baras Neurology
Miami, Florida
Site 25: University of South Florida
Tampa, Florida
Site 135: Augusta University Medical Center
Augusta, Georgia
Site 176: Hawaii Pacific Neuroscience
Honolulu, Hawaii
Site 188: North Shore Medical Group - Glenview
Glenview, Illinois
Site 156: Indiana University Health Neuroscience Center
Indianapolis, Indiana
Site 32: Kansas University Medical Center Research Institute
Kansas City, Kansas
Site 221: Neurology Center of New England
Foxborough, Massachusetts
Site 33: Detroit medical Center - University Health Center
Detroit, Michigan
Site 49: Michigan State University
East Lansing, Michigan
Site 127: University of Minnesota
Minneapolis, Minnesota
Site 134: Neurology and Sleep Disorders Clinic
Columbia, Missouri
Site 117: Las Vegas Clinic
Las Vegas, Nevada
Site 123: Northwell Health Neuroscience Institute
Great Neck, New York
Site 23: Hospital for Special Surgery
New York, New York
Site 47: Mount Sinai Hospital
New York, New York
Site 22: University of North Carolina
Chapel Hill, North Carolina
Site 15: Duke University
Durham, North Carolina
Site 122: Cleveland Clinic
Cleveland, Ohio
Site 38: Ohio State University
Columbus, Ohio
Site 40: Allegheny Neurological Associates
Pittsburgh, Pennsylvania
Site 128: Medical University of South Carolina
Charleston, South Carolina
Site 185: Neurology Clinic Cordova
Cordova, Tennessee
Site 131: Austin Neuromuscular Center
Austin, Texas
Site 19: University of Texas Southwestern
Dallas, Texas
Site 39: University of Utah
Salt Lake City, Utah
Site 164: University of Virginia Health System
Charlottesville, Virginia
Site 154: University of Washington
Seattle, Washington
Site 45: Center for Neurological Disorders
Milwaukee, Wisconsin
Site 44: London Health Sciences Centre University Hospital
London, Ontario, Canada
Site 11: Montreal Neurological Institute and Hospital (McGill University)
Montreal, Quebec, Canada
Site 191: Centre Hosptitalier Universitaire d'Angers
Angers, France
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.